Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic DMARDs in 2 US Health Care Claims Databases

Clinical Therapeutics

Volumn 38, Issue 6, 2016, Pages 1451-1463

  Harnett, James ^a   Curtis, Jeffrey R ^b   Gerber, Robert ^a   Gruben, David ^a   Koenig, Andrew ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

costs; Janus kinase inhibitor; real world experience; rheumatoid arthritis; tofacitinib; treatment patterns

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; OPIATE; SALAZOSULFAPYRIDINE; TOFACITINIB; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DATA BASE; DECISION MAKING; DISEASE ACTIVITY; DRUG COST; FEMALE; HEALTH CARE POLICY; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; ECONOMICS; FACTUAL DATABASE; MEDICATION COMPLIANCE; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES;

EID: 84964690824     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.038     Document Type: Article

References (53)

1. J.S. Smolen, D. Aletaha, M. Koeller, and et al. New therapies for treatment of rheumatoid arthritis Lancet 370 2007 1861 1874
2. R.N. Maini, F.C. Breedveld, J.R. Kalden, and et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
3. F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, and et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
4. E.C. Keystone, M.C. Genovese, L. Klareskog, and et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Ann Rheum Dis 68 2009 789 796
5. D. van der Heijde, L. Klareskog, V. Rodriguez-Valverde, and et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial Arthritis Rheum 54 2006 1063 1074
6. J. Zhang, F. Xie, E. Delzell, and et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients Arthritis Care Res (Hoboken) 67 2015 624 632
7. J. Listing, A. Strangfeld, R. Rau, and et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register Arthritis Res Ther 8 2006 R66
8. M.S. Heiberg, W. Koldingsnes, K. Mikkelsen, and et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study Arthritis Rheum 59 2008 234 240
9. M.M. Soliman, D.M. Ashcroft, K.D. Watson, and et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis 70 2011 583 589
10. US Food and Drug Administration. Enbrel® (etanercept) solution for subcutaneous use, highlights of prescribing information, 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/103795s5507lbl.pdf. Accessed March 28, 2016.
11. US Food and Drug Administration. Orencia® (abatacept): Highlights of prescribing information, 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125118s0138lbl.pdf. Accessed March 28, 2016.
12. US Food and Drug Administration. Humira® (adalimumab) injection for subcutaneous use, highlights of prescribing information, 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125057s232lbl.pdf. Accessed March 28, 2016.
13. H.E. Seymour, A. Worsley, J.M. Smith, and et al. Anti-TNF agents for rheumatoid arthritis Br J Clin Pharmacol 51 2001 201 208
14. M. Geyer, and U. Muller-Ladner Rationale of using different biological therapies in rheumatoid arthritis Arthritis Res Ther 12 2010 214
15. J.R. Curtis, and J.A. Singh Use of biologics in rheumatoid arthritis: current and emerging paradigms of care Clin Ther 33 2011 679 707
16. R. Fleischmann, J. Kremer, J. Cush, and et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 2012 495 507
17. R.F. van Vollenhoven, R. Fleischmann, S. Cohen, and et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med 367 2012 508 519
18. G.R. Burmester, R. Blanco, C. Charles-Schoeman, and et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 381 2013 451 460
19. J. Kremer, Z.G. Li, S. Hall, and et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial Ann Intern Med 159 2013 253 261
20. D. van der Heijde, Y. Tanaka, R. Fleischmann, and et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study Arthritis Rheum 65 2013 559 570
21. E.B. Lee, R. Fleischmann, S. Hall, and et al. Tofacitinib versus methotrexate in rheumatoid arthritis N Engl J Med 370 2014 2377 2386
22. US Food and Drug Administration. Xeljanz® (tofacitinib) tablets for oral administration [prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203214s000lbl.pdf. Accessed March 28, 2016.
23. J.A. Singh, K.G. Saag, S.L. Bridges Jr, and et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis Arthritis Rheumatol 68 2015 1 26
24. J.S. Smolen, R. Landewé, F.C. Breedveld, and et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann Rheum Dis 73 2014 492 509
25. M.E. Charlson, P. Pompei, K.L. Ales, and et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
26. G. Ting, S. Schneeweiss, R. Scranton, and et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study Arthritis Res Ther 10 2008 R95
27. A.M. Peterson, D.P. Nau, J.A. Cramer, and et al. A checklist for medication compliance and persistence studies using retrospective databases Value Health 10 2007 3 12
28. S. Curkendall, V. Patel, M. Gleeson, and et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59 2008 1519 1526
29. P. Li, M.A. Blum, J. Von Feldt, and et al. Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis Value Health 13 2010 805 812
30. Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence, 2012. http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf. Accessed March 28, 2016.
31. L.M. Hess, M.A. Raebel, D.A. Conner, and et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures Ann Pharmacother 40 2006 1280 1288
32. Zhao B, Wong EC, Palaniappan L. Estimating Patient Adherence to Medication with Electronic Health Records Data and Pharmacy Claims Combined. Abstract presented at: SAS Global Forum. 2013.
33. J. Tkacz, L. Ellis, S.C. Bolge, and et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients Clin Ther 36 2014 737 747
34. M. Dougados, K. Kissel, T. Sheeran, and et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann Rheum Dis 72 2013 43 50
35. M.E. Weinblatt, J. Kremer, J. Cush, and et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study Arthritis Care Res (Hoboken) 65 2013 362 371
36. V.P. Bykerk, A.J. Östör, J. Alvaro-Gracia, and et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice Clin Rheumatol 34 2015 563 571
37. C. Gabay, M. Riek, M.L. Hetland, and et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study Ann Rheum Dis 2015 [Epub ahead of print]
38. G.R. Burmester, W.F. Rigby, R.F. van Vollenhoven, and et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial Ann Rheum Dis 2015 [Epub ahead of print]
39. R.J. Moots, B. Haraoui, M. Matucci-Cerinic, and et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice Clin Exp Rheumatol 29 2011 26 34
40. M.M. Bonafede, S.R. Gandra, K.M. Fox, and et al. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years after therapy initiation J Med Econ 15 2012 635 643
41. R.J. Moots, R. Mays, J. Stephens, and et al. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs Clin Exp Rheumatol 33 2015 737 745
42. K.M. Stockl, J.S. Shin, H.C. Lew, and et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence J Manag Care Pharm 16 2010 593 604
43. L.H. Chu, A.A. Kawatkar, and S.E. Gabriel Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients Clin Ther 37 2015 660 666
44. C.G. Grijalva, C.P. Chung, P.G. Arbogast, and et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis Med Care 45 Suppl 2007 S66 S76
45. L.E. Kristensen, T. Saxne, J.A. Nilsson, and et al. Impact of concurrent DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden Arthritis Res Ther 8 2006 R174
46. A. Zink, J. Listing, S. Kary, and et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy Ann Rheum Dis 64 2005 1274 1279
47. S.M. Du Pan, S. Dehler, A. Ciurea, and et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis Arthritis Rheum 61 2009 560 568
48. T. Koncz, M. Pentek, V. Brodszky, and et al. Adherence to biologic DMARD therapies in rheumatoid arthritis Expert Opin Biol Ther 10 2010 1367 1378
49. R.J. Desai, D.H. Solomon, M.E. Weinblatt, and et al. An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score Arthritis Res Ther 17 2015 83
50. J.R. Curtis, B. Chastek, L. Becker, and et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population J Manag Care Spec Pharm 21 2015 318 329
51. J.R. Curtis, V.F. Schabert, J. Yeaw, and et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis J Med Econ 17 2014 555 566
52. A. Oladapo, J.C. Barner, K.A. Lawson, and et al. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis J Manag Care Spec Pharm 20 2014 657 667
53. A. Kavanaugh, G.W. Reed, K.C. Saunders, and et al. Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United Sates after food and drug administration approval: results from the CORRONA US rheumatoid arthritis registry Ann Rheum Dis 74 2015 1040